You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

EMPLICITI Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: EMPLICITI
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for EMPLICITI
Recent Clinical Trials for EMPLICITI

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Washington University School of MedicinePhase 1
Paula C. & Rodger O. Riney Blood Cancer ResearchPhase 1
Abdullah KhanPhase 1

See all EMPLICITI clinical trials

Pharmacology for EMPLICITI
Mechanism of ActionSLAMF7-directed Antibody Interactions
Established Pharmacologic ClassSLAMF7-directed Immunostimulatory Antibody
Chemical StructureAntibodies, Monoclonal
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EMPLICITI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EMPLICITI Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for EMPLICITI Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: EMPLICITI

Introduction

EMPLICITI, developed by Bristol Myers Squibb (BMS), is an immunostimulatory antibody that targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7) and is used in the treatment of multiple myeloma. Here, we delve into the market dynamics and financial trajectory of EMPLICITI since its FDA approval in 2015.

FDA Approval and Initial Market Performance

EMPLICITI received FDA approval in 2015 for the treatment of patients with multiple myeloma who have received one to three prior therapies, in combination with Revlimid and dexamethasone[1][5].

  • Initially, EMPLICITI generated a revenue of USD 150 million in 2015, indicating a promising start in the multiple myeloma treatment market.

Market Competition and Growth Challenges

The multiple myeloma treatment market is highly competitive, with several key players, including Janssen's DARZALEX. Despite being approved at the same time as DARZALEX, EMPLICITI's growth has been significantly slower.

  • DARZALEX has dominated the market with continuous label expansions and the introduction of a subcutaneous formulation, achieving a revenue of nearly USD 9.7 billion in 2023. In contrast, EMPLICITI's revenue peaked at USD 380 million in 2020 and then declined[1].

Clinical Trial Setbacks

A significant setback for EMPLICITI was the results of the ELOQUENT-1 clinical trial. The trial failed to show a statistically significant improvement in progression-free survival (PFS) when EMPLICITI was added to a regimen of Revlimid and dexamethasone (Rd) in patients with newly diagnosed, untreated multiple myeloma who were transplant ineligible[5].

  • This outcome hindered EMPLICITI's ability to gain traction in the first-line treatment segment, a critical area for market dominance.

Impact of Portfolio Changes at BMS

Following BMS's acquisition of Celgene in 2019, the company's focus shifted towards other successful drugs like REVLIMID and POMALYST. These drugs generated significant revenue, with REVLIMID alone reaching global revenues of $12.8 billion in its peak year[1].

  • This shift relegated EMPLICITI to a minor role within BMS's extensive multiple myeloma portfolio, further impacting its market performance.

Revenue Trends

  • EMPLICITI's revenue declined from USD 334 million in 2021 to USD 296 million in 2022, representing an 11% decline. This downward trend continued, with global revenue for EMPLICITI in 2022 being significantly lower than its peak in 2020[1].

Market Landscape and Competitive Dynamics

The biological drugs market, including monoclonal antibodies like EMPLICITI, is experiencing robust growth driven by factors such as increasing prevalence of chronic diseases and advancements in biotechnology. However, the market is highly competitive, with other monoclonal antibodies and emerging therapies like CAR-T cells and bispecific antibodies[2].

  • Janssen, with its diversified portfolio including DARZALEX, CARVYKTI, and other multiple myeloma treatments, continues to dominate the market. This competitive landscape makes it challenging for EMPLICITI to regain significant market share[1].

Regional Market Insights

The global biological drugs market, including the segment for multiple myeloma treatments, is largely driven by regions like North America and Europe. These regions have well-developed pharmaceutical industries, advanced healthcare facilities, and widespread insurance coverage, which facilitate the adoption of new biologic therapies[2].

  • However, EMPLICITI's performance has not been strong enough to capitalize on these favorable market conditions.

Future Outlook and Challenges

Given the current market dynamics, EMPLICITI faces significant challenges in regaining its market position. The drug's failure to show significant improvement in clinical trials and the dominance of other treatments like DARZALEX make it difficult for EMPLICITI to compete effectively.

  • The biological drugs market is expected to continue growing, driven by innovations and increasing demand for personalized medicine. However, EMPLICITI's trajectory suggests that it may remain a minor player in this expanding market[2].

Key Takeaways

  • EMPLICITI was approved by the FDA in 2015 but has seen slower growth compared to other treatments like DARZALEX.
  • Clinical trial setbacks, particularly the ELOQUENT-1 trial, have hindered its adoption in the first-line treatment segment.
  • BMS's acquisition of Celgene and the subsequent focus on other successful drugs have relegated EMPLICITI to a minor role.
  • The competitive landscape and market dynamics favor other treatments, making it challenging for EMPLICITI to regain significant market share.

FAQs

What is EMPLICITI used for?

EMPLICITI is an immunostimulatory antibody used in the treatment of multiple myeloma. It targets the SLAMF7 protein and is used in combination with other drugs like Revlimid and dexamethasone.

Why has EMPLICITI's revenue declined?

EMPLICITI's revenue has declined due to several factors, including the failure to show significant improvement in clinical trials, the dominance of other treatments like DARZALEX, and the shift in BMS's focus towards other successful drugs.

What was the outcome of the ELOQUENT-1 clinical trial for EMPLICITI?

The ELOQUENT-1 clinical trial failed to show a statistically significant improvement in progression-free survival (PFS) when EMPLICITI was added to a regimen of Revlimid and dexamethasone in patients with newly diagnosed, untreated multiple myeloma who were transplant ineligible.

How does EMPLICITI compare to DARZALEX in terms of market performance?

DARZALEX has significantly outperformed EMPLICITI in the multiple myeloma treatment market, achieving a revenue of nearly USD 9.7 billion in 2023 compared to EMPLICITI's peak revenue of USD 380 million in 2020.

What are the future prospects for EMPLICITI in the biological drugs market?

Given the current market dynamics and competitive landscape, EMPLICITI's future prospects appear challenging. The drug is likely to remain a minor player in the expanding biological drugs market.

Sources

  1. DARZALEX and EMPLICITI Multiple Myeloma Treatment Drugs Landscape - DelveInsight
  2. Biological Drugs Market: Global Industry Analysis - Maximize Market Research
  3. Multiple Myeloma Drugs Market and Forecast 2024-2031 - iHealthcareAnalyst
  4. Biologics Market Dynamics: Setting the Stage for Biosimilars - FTC
  5. Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study - Bristol Myers Squibb News
Last updated: 2024-12-17

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.